Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse ...

College of Science won best oral presentation during the National University of Singapore Science Summer Institute (NUS SSI) 2024 at the NUS campus in Singapore. Greville Galindon III, a BS Biology in ...

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of ...

The oral presentation will highlight safety and efficacy data from three cohorts of ARC-20, which evaluated casdatifan monotherapy in patients that had received both prior TKI and anti-PD-1 therapy.

Abstract Title: Safety and Efficacy of DYNE-101 in Adults with DM1: Phase 1/2 ACHIEVE Trial Data Date and Time: Wednesday, March 19, at 12:30-12:45 p.m. CT Presenter: James Lilleker M.D., Neurologist, ...

PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), today announced that two oral presentations and 20 ...

Amicus Therapeutics announced that it will showcase two oral presentations and 20 posters related to its research on Fabry and Pompe diseases at the 21st Annual WORLDSymposium™ 2025 taking place ...

“We are pleased to share the updated Phase 2 data through a late-breaking oral presentation at this year’s International Stroke Conference. These preliminary results show promising MRI-based ...

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse eventsIn comparison to placebo, treatment with REC-994 400 mg showed promi ...